DEF 14C: Onconetix Secures $2 Million PIPE Financing and Establishes Equity Line of Credit

Onconetix, Inc. has entered into agreements for a $2 million private placement (PIPE) and a committed equity facility (ELOC) to bolster its working capital.

Summary

• Onconetix, Inc. entered into a Securities Purchase Agreement for a private placement (PIPE Financing) with six institutional investors on October 2, 2024.
• The PIPE Financing involves the sale of 3,499 shares of Series C convertible preferred stock at a stated value of $1,000 per share, along with warrants to purchase 591,856 shares of common stock, generating $2.0 million in gross proceeds.
• Concurrently, Onconetix entered into a Common Stock Purchase Agreement for a Committed Equity Facility (ELOC) with an institutional investor.
• The ELOC allows Onconetix to sell newly issued common stock to the ELOC Purchaser from time to time to support general corporate and working capital needs.
• The company may direct the ELOC Purchaser to purchase up to 100,000 shares of Common Stock at a purchase price equal to the lesser of 90% of (i) the daily volume weighted average price (the VWAP) of the Common Stock for the five trading days immediately preceding the applicable Purchase Date for such Fixed Purchase and (ii) the lowest sale price of a share of Common Stock on the applicable Purchase Date for such Fixed Purchase during the full trading day on such applicable Purchase Date.
• The company agreed to file a registration statement covering the issuance and sale of the maximum number of ELOC Shares issuable under the ELOC Purchase Agreement as may be permitted under applicable rules.
• The company agreed to use its commercially reasonable efforts to cause the registration statement to be filed within 45 days after the closing of the ELOC Purchase Agreement and to have such registration statement effective within 120 days of such closing (or 90 days of such closing if the Company is notified by the Securities and Exchange Commission (the SEC). that such registration statement will not be reviewed or subject to further review).
• The transactions were approved by the Board of Directors, and a majority of voting stockholders approved the issuance of common stock upon conversion/exercise of the Series C Preferred Stock/Warrants and in connection with the ELOC Purchase Agreement on October 11, 2024.
• The actions will become effective on November 21, 2024, 20 calendar days after the mailing of the information statement to stockholders.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company is securing funding, which is generally positive, but the terms of the financing, including potential dilution and restrictive covenants, temper the overall outlook.

Positives

• The PIPE Financing provides an immediate infusion of $2.0 million to strengthen the company's financial position.
• The ELOC provides a flexible mechanism for raising additional capital as needed, supporting the company's working capital requirements.
• Stockholder approval removes a potential hurdle related to Nasdaq listing rules, allowing for the conversion/exercise of securities and issuance of ELOC shares.
• The company retains control over the timing and amount of sales of ELOC Shares to the Purchaser over the 36-month period from and after the Commencement Date.

Negatives

• The PIPE Financing involves the issuance of convertible preferred stock and warrants, which could dilute existing shareholders upon conversion/exercise.
• The ELOC relies on the company's ability to maintain a common stock price above $0.05 to effectively utilize the facility.
• The Series C Preferred Stock includes provisions for default dividends at a rate of 15% per annum during Triggering Events, increasing the cost of capital if such events occur.
• The company is subject to various covenants and restrictions under the Certificate of Designations, potentially limiting its operational flexibility.

Risks

• The company's ability to access the ELOC is contingent upon satisfying certain conditions, including the effectiveness of a registration statement.
• The conversion price of the Series C Preferred Stock and the exercise price of the warrants are subject to adjustment, potentially leading to further dilution.
• The company is subject to Triggering Events that could result in adverse consequences, such as the accrual of default dividends and the potential for alternate conversion rights.
• The company's stock price could be negatively impacted by the issuance of new shares under the ELOC, particularly if sales are made at a discount to market prices.
• The company is subject to the risk of not maintaining authorized, but unissued shares equal to 150% of the shares underlying the Series C Preferred Stock and the Warrants.

Future Outlook

The company intends to use the proceeds from the PIPE Financing and the ELOC to support its general corporate and working capital requirements. The company will control the timing and amount of any sales of ELOC Shares to the Purchaser over the 36-month period from and after the Commencement Date.

Industry Context

PIPE financings and ELOCs are common tools for small-cap companies to raise capital, particularly in the biotechnology and healthcare sectors. These financing structures can provide flexibility but also come with risks of dilution and potential downward pressure on the stock price.

Comparison to Industry Standards

• The terms of the PIPE financing, including the conversion price and warrant exercise price, appear to be within the range of similar transactions in the micro-cap space.
• The ELOC structure is comparable to those used by other companies seeking to access capital markets on an as-needed basis.
• However, the specific terms, such as the discount to market price for ELOC share sales and the default dividend rate on the Series C Preferred Stock, should be compared to industry benchmarks to assess their favorability.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• The company's employees and operations will benefit from the increased financial stability.
• The company's customers and suppliers may see improved reliability and service due to the strengthened financial position.
• Creditors may view the company more favorably due to the increased access to capital.

Next Steps

• The company will file a registration statement for the resale of shares of Common Stock underlying the Series C Preferred Stock and the Warrants.
• The company will work to satisfy the conditions to commence sales of Common Stock to the Purchaser under the ELOC Purchase Agreement.
• The company will monitor for Triggering Events and take appropriate action to cure them if they occur.

Key Dates

Keywords

PIPE Financing, ELOC, Series C Preferred Stock, Warrants, Common Stock, Equity Financing, Onconetix